2022
DOI: 10.36416/1806-3756/e20220083
|View full text |Cite
|
Sign up to set email alerts
|

Determinants of death in critically ill COVID-19 patients during the first wave of COVID-19: a multicenter study in Brazil

Abstract: Avaliar desfechos clínicos e fatores associados à mortalidade, com foco em infecções secundárias, em pacientes com COVID-19 em estado crítico em três hospitais brasileiros durante a primeira onda da pandemia. Métodos: Estudo observacional retrospectivo envolvendo pacientes adultos com COVID-19 internados nas UTIs participantes entre março e agosto de 2020. Analisaram-se características clínicas, comorbidades, fonte de infecção por SARS-CoV-2, dados laboratoriais, dados microbiológicos, complicações e causas de… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 38 publications
0
2
0
Order By: Relevance
“…Twenty studies included only patients admitted to the ICU [ 21 , 23 , 25 , 26 , 28 , 31 – 33 , 36 40 , 44 48 , 53 , 54 ], five studies included patients admitted to a COVID-19-dedicated HDU [ 29 , 30 , 34 , 35 , 43 ], eight studies included patients who were admitted to both HDU and ICU [ 22 , 24 , 27 , 41 , 42 , 49 , 50 , 52 ], and one study included Emergency Department patients who were later admitted either to ICU [ 51 ]. Thirty-one studies included data about patients who received vs. patients who did not receive vasopressors [ 21 38 , 40 49 , 51 , 53 , 54 ] and were included in review. Moreover, three studies included patients who received angiotensin-II [ 39 , 50 , 52 ] and, out of those, two compared the use of angiotensin-II with other vasopressors [ 50 , 52 ] (Additional file 3 : Appendix C2).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Twenty studies included only patients admitted to the ICU [ 21 , 23 , 25 , 26 , 28 , 31 – 33 , 36 40 , 44 48 , 53 , 54 ], five studies included patients admitted to a COVID-19-dedicated HDU [ 29 , 30 , 34 , 35 , 43 ], eight studies included patients who were admitted to both HDU and ICU [ 22 , 24 , 27 , 41 , 42 , 49 , 50 , 52 ], and one study included Emergency Department patients who were later admitted either to ICU [ 51 ]. Thirty-one studies included data about patients who received vs. patients who did not receive vasopressors [ 21 38 , 40 49 , 51 , 53 , 54 ] and were included in review. Moreover, three studies included patients who received angiotensin-II [ 39 , 50 , 52 ] and, out of those, two compared the use of angiotensin-II with other vasopressors [ 50 , 52 ] (Additional file 3 : Appendix C2).…”
Section: Resultsmentioning
confidence: 99%
“…Twenty-two out of the 34 included studies provided data on in-hospital mortality in patients who received vs. patients who did not receive vasopressors, resulting in a total population of 8034 individuals [ 26 , 28 , 32 – 38 , 40 49 , 51 , 53 , 54 ]. Due to high heterogeneity (I 2 : 94%, P Q < 0.001), the random-effects model was implemented.…”
Section: Resultsmentioning
confidence: 99%